NCT02313740View on ClinicalTrials.gov

Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Influenza
Interventions
BIOLOGICAL

Butantan Fragmented Inactivated Trivalent Influenza Vaccine

Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).

Sponsors

Lead Sponsor

Butantan Institute
All Listed Sponsors
lead

Butantan Institute

OTHER_GOV